Latest News

Despite an already strong run, Sanwayuka Industry Corporation ( TSE:4125 ) shares have been powering on, with a gain of...

If you are wondering whether Fidelis Insurance Holdings is a sleeper value play or a stock to avoid, you are in the right place. We are going to unpack what the current price is really telling us about the business. Despite a modest 0.6% gain year to date and a near flat 30 day move of 0.1%, the stock is still down 7.9% over the past year after a recent 5.0% pullback over the last week, which can leave investors unsure whether this is a buying opportunity or a warning sign. Recent news...

Zumtobel Group (WBAG:ZAG) has just posted Q2 2026 numbers with revenue of about €271 million and EPS of €0.41, setting a clearer earnings picture after a volatile run of recent quarters. The company has seen quarterly revenue move from roughly €289 million in Q1 2025 to €271 million in Q2 2026, while EPS has swung between €0.30 and negative territory over that stretch, underscoring how much the earnings story now hinges on where margins settle from here. See our full analysis for Zumtobel...

DAE HWA Pharmaceutical Co., Ltd.'s ( KOSDAQ:067080 ) price-to-sales (or "P/S") ratio of 2.2x may not look like an...

Sungdo Engineering & Construction Co., Ltd. ( KOSDAQ:037350 ) shareholders have had their patience rewarded with a 27...

Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...

Absci Corporation recently dosed the first healthy volunteers in its Phase 1/2a HEADLINE trial of ABS-201, an AI-designed anti-prolactin receptor antibody for androgenetic alopecia, with interim data planned for the second half of 2026. The company also aims to leverage safety and pharmacokinetic insights from this study to accelerate development of ABS-201 for endometriosis, potentially broadening the drug’s addressable patient population. Against this backdrop, we’ll examine how the...

Key Insights The considerable ownership by individual investors in Plenti Group indicates that they collectively have a...

6K Additive (ASX:6KA) has released its H1 2025 numbers, posting total revenue of about $9.7 million alongside a net loss of roughly $12.8 million. This leaves investors weighing modest top line progress against ongoing red ink. The company has seen revenue move from around $7.7 million in H1 2024 to $9.7 million in H1 2025. Meanwhile, trailing 12 month revenue sits near $20.4 million against a net loss of about $26.6 million, underscoring a business that is expanding sales but still running...

Key Insights Institutions' substantial holdings in Syrah Resources implies that they have significant influence over...

Investors who take an interest in Manhattan Corporation Limited ( ASX:MHC ) should definitely note that the...

From what we can see, insiders were net sellers in Ora Banda Mining Limited's ( ASX:OBM ) during the past 12 months...

Transurban Group's ( ASX:TCL ) dividend will be increasing from last year's payment of the same period to A$0.34 on...

Walmart (WMT) just posted its Q3 2026 numbers, with revenue of about $179.5 billion and net income of roughly $6.1 billion translating to EPS of $0.77 as investors focus on how these figures feed into the retailer’s earnings momentum story. The company has seen revenue move from around $169.6 billion in Q3 2025 to $179.5 billion in Q3 2026, while trailing twelve month net income climbed from about $19.4 billion to $22.9 billion. This sets the stage for investors to parse how sustained...

Black Diamond Therapeutics recently reported topline Phase 2 data for silevertinib in first-line non-small cell lung cancer patients with non-classical EGFR mutations, and outlined plans to start a randomized Phase 2 trial in newly diagnosed glioblastoma in 2026. The early results, including strong central nervous system response rates and a broad range of EGFR alterations targeted, underscore silevertinib’s potential as a brain-penetrant precision therapy across multiple tumor types. We’ll...

It hasn't been the best quarter for Hess Midstream LP ( NYSE:HESM ) shareholders, since the share price has fallen 16...

As the Canadian market navigates through policy shifts and global uncertainties, the TSX is on track for its strongest calendar-year return since 2009, rewarding investors who stayed committed during periods of volatility. In this context, understanding what makes a good investment becomes crucial; penny stocks, while an older term, continue to offer intriguing opportunities for growth. These stocks often represent smaller or newer companies that can pair strong financial health with...

Green Cross Health Limited ( NZSE:GXH ) recently posted some strong earnings, and the market responded positively. We...

As the U.S. stock market experiences a modest uptick following key inflation data, major indices like the Dow Jones and S&P 500 are nearing all-time highs, reflecting investor optimism despite recent economic uncertainties. In this environment, identifying stocks that are trading below their intrinsic value can offer potential opportunities for investors seeking to capitalize on undervalued assets amid fluctuating market conditions.

U.S. stock indexes have recently ticked higher following key inflation data, suggesting cautious optimism among investors as they anticipate upcoming Federal Reserve policy decisions. In the context of this market environment, penny stocks remain a notable area for investors seeking potential growth opportunities outside of traditional blue-chip companies. Though the term "penny stocks" may seem outdated, these smaller or newer companies can still offer significant value and growth potential...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

This article explores whether MNTN is a beaten-down bargain or a value trap at current levels, and what the market might be overlooking. After sliding 48.8% year to date and another 9.2% over the last month, the stock has only managed a modest 0.7% uptick in the past week. This mix hints at both lingering caution and potential rebound interest. Recent headlines have focused on MNTN’s positioning in the evolving media and ad tech landscape, including its push to differentiate in a crowded...

There wouldn't be many who think GCC, S.A.B. de C.V.'s ( BMV:GCC ) price-to-earnings (or "P/E") ratio of 11.7x is worth...

With its stock down 5.7% over the past week, it is easy to disregard TIM (BVMF:TIMS3). However, stock prices are...